Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipromlimab + tuvonralimab + albumin-bound paclitaxel + nedaplatin
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination neoadjuvant therapy regimen consists of **ipromlimab** (an anti-CTLA-4 monoclonal antibody), **tuvonralimab** (a bifunctional antibody targeting PD-1 and CTLA-4), **albumin-bound paclitaxel** (a microtubule inhibitor), and **nedaplatin** (a platinum-based DNA alkylating agent). The regimen is currently being investigated in a Phase II clinical trial sponsored by **Sun Yat-sen University** for the treatment of locally advanced resectable esophageal squamous cell carcinoma (ESCC). Ipromlimab enhances T-cell activation by blocking the CTLA-4 checkpoint, while tuvonralimab provides dual blockade of the PD-1 and CTLA-4 pathways. The addition of chemotherapy (paclitaxel and nedaplatin) is intended to provide synergistic anti-tumor activity, potentially increasing the pathological complete response (pCR) rate and improving surgical outcomes in the neoadjuvant setting.
- Brand names
- AbraxaneAqupla
- Other names
- nab-paclitaxelnanoparticle albumin-bound paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA
Beyond the preview
Go deeper on ipromlimab + tuvonralimab + albumin-bound paclitaxel + nedaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipromlimab + tuvonralimab + albumin-bound paclitaxel + nedaplatin.